Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
168.4 USD | +0.24% |
|
+0.52% | +9.00% |
12/07 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
12/07 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.00% | 297B | |
+63.90% | 856B | |
+39.45% | 631B | |
-4.02% | 359B | |
+17.82% | 325B | |
+5.81% | 234B | |
+16.65% | 226B | |
+16.28% | 177B | |
+2.13% | 165B | |
+2.42% | 126B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc., Q4 2016 Earnings Call, Jan 27, 2017